Ricolinostat, the first-in-class HDAC6 selective inhibitor, has recently demonstrated acceptable tolerability and preliminary evidence of anti-myeloma efficacy upon combination treatment with lenalidomide and dexamethasone, as well as pharmacodynamic evidence of both HDAC6 and Class I HDAC inhibition in patients [28]. Here, HDAC6 is linked to plasma cell myeloma.